Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesJan 13 07:20 ET · Ratings

H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $3

Moomoo NewsJan 13 06:31 ET · Ratings

Barinthus Biotherapeutics Restructures to Focus on Immunotherapy

TipRanksJan 10 08:33 ET

Barinthus Bio Restructures, Prioritizes VTP-1000 For Celiac Disease With Phase 1 Data In Mid-2025, Pauses VTP-300 For Hepatitis B Pending Partner; Cuts 65% Workforce, Closes U.K. Site To Extend Cash To 2027 With $112M Reserves; Focuses U.S. Operations...

BenzingaJan 10 08:07 ET

Press Release: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Dow JonesJan 10 08:00 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaDec 13, 2024 16:06 ET